non-CR patients before transplant in mantle cell lymphoma
نویسندگان
چکیده
Nordic MCL3 study: Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma Arne Kolstad, Anna Laurell, Mats Jerkeman, Kirsten Grønbæk, Erkki Elonen, Riikka Räty, Lone Bredo Pedersen, Annika Loft, Trond Velde Bogsrud, Eva Kimby, Per Boye Hansen, Unn-Merete Fagerli, Herman Nilsson-Ehle, Grete Fossum Lauritzsen, Anne Kristine Lehmann, Christer Sundstrom, Marja-Liisa Karjalainen-Lindsberg, Elisabeth Ralfkiaer, Mats Ehinger, Jan Delabie, Hans Bentzen, Jukka Schildt, Kamelia Kostova-Aherdan, Henrik Frederiksen, Peter de Nully Brown, and Christian H. Geisler, on behalf of the Nordic Lymphoma Group
منابع مشابه
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
The main objective of the MCL3 study was to improve outcome for patients not in complete remission (CR) before transplant by adding (90)Y-ibritumomab-tiuxetan (Zevalin) to the high-dose regimen. One hundred sixty untreated, stage II-IV mantle cell lymphoma patients <66 years received rituximab (R)-maxi-CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) alternating with R-...
متن کاملMantle Cell Lymphoma with Multiple Lymphomatous Polyposis Presenting With Intussusceptions
Mantle cell lymphoma is an aggressive type of B-cell non-Hodgkin's lymphoma that originates from small to medium sized lymphocytes located in the mantle zone of the lymph node. The gastrointestinal tract is the predominant site of extranodal involvement in the form of multiple lymphomatous polyposis. Multiple lymphomatous polyposis due to mantle cell lymphoma presenting with intussusception is ...
متن کامل8.01.529 Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas
Non-Hodgkin Lymphoma (NHL) B-Cell aggressive subtype (except mantle cell) Myeloablative autologous, myeloablative allogeneic or reduced-intensity conditioning (RIC) allogeneic HSCT with curative intent may be considered medically necessary: As salvage for patients not in complete remission (CR) after first line chemotherapy induction; To achieve or consolidate a CR in chemotherapy sensitive...
متن کاملUnmet needs in the treatment of mantle cell lymphoma.
Mantle cell lymphoma is one of the most challenging hematologic malignancies, owing to an aggressive disease course, a high rate of relapse, and lack of standard of care. In the United States, mantle cell lymphoma accounts for approximately 6% of all newly diagnosed cases of non-Hodgkin lymphoma. Because most patients are initially diagnosed with advanced-stage disease, they are often symptomat...
متن کاملRelapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for hematologic malignancies depends on graft-versus-tumor effects for eradication of cancer. Here, we estimated relapse risks according to disease characteristics. Between 1997 and 2006, 834 consecutive patients (median age, 55 years; range, 5-74 years) received related (n = 498) or unrelated (n = 336) HCT ...
متن کامل